Gastric Cancer
📧 Sign up to get email alerts when something new happens for Gastric Cancer.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-06-21FDA Approved: CAPECITABINE — Original Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved Sun Pharmaceutical Industries' original application for Capecitabine, granting a generic version of the cancer drug Capecit…
-
CLINICAL_TRIALS trial_result · 2019-06-19Clinical Trial Update: 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer [Phase 2, Phase 3]
Clinical trial comparing FLOT vs ECF regimens in locally advanced, resectable gastric cancer has completed phases 2 and 3.
-
CLINICAL_TRIALS trial_result · 2019-06-14Clinical Trial Update: Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage [Phase 2]
Phase 2 trial reporting results for rapid staging of gastric and pancreatic cancers using peritoneal lavage.
-
FDA approval · 2019-06-13FDA Approved: KANJINTI — Original Application (Amgen, Inc)
FDA approves KANJINTI (trastuzumab-anns) from Amgen as a biosimilar to trastuzumab. It is approved for HER2-overexpressing breast cancer and…
-
CLINICAL_TRIALS trial_result · 2019-06-05Clinical Trial Update: Oncoxin® and Quality of Life in Cancer Patients [Phase 4]
Phase 4 clinical trial update assessing Oncoxin’s impact on quality of life in cancer patients; completed status.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-05-31Clinical Trial Update: S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC） [Phase 3]
Phase 3 clinical trial evaluating 9 months of S-1 therapy versus 12 months in stage II gastric cancer; currently recruiting.
-
CLINICAL_TRIALS trial_result · 2019-05-23Clinical Trial Update: Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer [Phase 3]
A Phase 3 clinical trial evaluating standard versus super-extended lymphadenectomy after neoadjuvant chemotherapy for locally advanced gastr…
-
CLINICAL_TRIALS trial_result · 2019-05-17Clinical Trial Update: Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer [Phase 2]
Exploratory Phase 2 clinical study evaluating apatinib in combination with a PD-1 inhibitor for advanced gastric cancer.
-
CLINICAL_TRIALS trial_result · 2019-05-16Clinical Trial Update: Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer [Phase 2]
Phase 2 clinical trial evaluating oxaliplatin, capecitabine (Xeloda), and cetuximab as first-line therapy for metastatic or unresectable gas…
-
CLINICAL_TRIALS trial_result · 2019-05-15Clinical Trial Update: Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer [Phase 2]
A Phase 2 trial evaluating apatinib in combination with S-1 as maintenance therapy for HER-2 negative gastric cancer.
-
CLINICAL_TRIALS withdrawal · 2019-05-08Clinical Trial Update: Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB. [Phase 3]
Phase 3 clinical trial comparing S-1 for 6 months to 1 year as adjuvant chemotherapy after D2 gastrectomy in gastric cancer (stages II, IIIA…
-
CLINICAL_TRIALS trial_result · 2019-05-07Clinical Trial Update: Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer [Phase 2]
Phase 2 trial update evaluating telatinib added to capecitabine/oxaliplatin in first-line gastric or GEJ cancer.
-
CLINICAL_TRIALS trial_result · 2019-04-19Clinical Trial Update: Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach [Phase 2]
Phase 2 clinical trial update for EOF (epirubicin, oxaliplatin, and fluorouracil) in esophageal, gastroesophageal junction, or stomach cance…
-
FDA approval · 2019-04-17FDA Approved: OGIVRI — Supplemental Application (Biocon Biologics Inc.)
The FDA approved Biocon Biologics' supplemental application for OGIVRI (trastuzumab-dkst), a trastuzumab biosimilar.
-
CLINICAL_TRIALS trial_result · 2019-04-17Clinical Trial Update: Oral Nutritional Supplements Compared With Standard Diet in Postoperative Gastric Cancer Patients With Adjuvant Chemotherapy [Phase 3]
Phase 3 clinical trial update comparing oral nutritional supplements with standard diet in postoperative gastric cancer patients receiving a…
-
CLINICAL_TRIALS trial_result · 2019-04-09Clinical Trial Update: Biomarker Study of PDR001 in Combination With MCS110 in Gastric Cancer [Phase 2]
Phase 2 biomarker study evaluating PDR001 in combination with MCS110 in gastric cancer.
-
CLINICAL_TRIALS trial_result · 2019-04-08Clinical Trial Update: A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC) [Phase 2]
Phase 2 trial evaluating Kadcyla (trastuzumab emtansine) plus capecitabine in HER2-positive metastatic breast cancer or HER2-positive locall…
-
CLINICAL_TRIALS trial_result · 2019-04-02Clinical Trial Update: Gastric Cancer RAD001 Study [Phase 1, Phase 2]
Phase 1/2 clinical trial update for RAD001 in gastric cancer conducted by the Chinese University of Hong Kong has completed recruitment.
-
FDA approval · 2019-04-01FDA Approved: DOCETAXEL — Supplemental Application (Dr. Reddy's Laboratories Inc.)
FDA approved a supplemental application for Docetaxel from Dr. Reddy's Laboratories Inc., authorizing the generic product under the approved…
-
CLINICAL_TRIALS trial_result · 2019-03-15Clinical Trial Update: Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer. [Phase 2]
Phase II clinical trial evaluating CHFR methylation status in patients with metastatic esophageal, gastroesophageal, and gastric cancers; st…
-
FDA approval · 2019-03-13FDA Approved: DOCETAXEL ANHYDROUS — Supplemental Application (Meitheal Pharmaceuticals Inc)
The FDA approved a supplemental application from Meitheal Pharmaceuticals to market docetaxel anhydrous as a generic chemotherapy drug.
-
CLINICAL_TRIALS trial_result · 2019-02-28Clinical Trial Update: Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers [Phase 3]
Phase 3 trial evaluating early palliative care added to standard care versus standard care alone in patients with incurable lung or non-colo…
-
CLINICAL_TRIALS trial_result · 2019-02-27Clinical Trial Update: Postoperative Enteral Immunonutrition in Gastric Cancer [Phase 3]
Phase 3 clinical trial update on postoperative enteral immunonutrition in gastric cancer has completed.
-
CLINICAL_TRIALS trial_result · 2019-02-27Clinical Trial Update: NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma [Phase 2]
Phase 2 trial evaluating nab-paclitaxel plus FOLFOX as perioperative chemotherapy for operable oesogastric adenocarcinoma.
-
CLINICAL_TRIALS trial_result · 2019-02-25Clinical Trial Update: First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer. [Phase 2]
Phase 2 trial evaluating irinotecan, capecitabine, and oxaliplatin as first-line therapy for metastatic gastric or gastroesophageal cancer h…